Karyopharm Therapeutics (KPTI) PT Raised to $9 at RBC Capital
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.99 -1.97%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $9.00 (from $8.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Asia Vital Components Co Ltd (3017:TT) PT Raised to NT$4,250 at Macquarie
- Ascendis Pharma (ASND) PT Raised to $333 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
